Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD
Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
In the present study, the investigators wish to address the effect of a
glucocorticoid/long-acting beta-agonist preparation on endothelial function in COPD patients
who do not currently smoke (ex-smokers) by measuring endothelium-dependent (albuterol
response) and endothelium-independent (NTG response) vasodilation in the bronchial artery,
reflecting endothelium-dependent and endothelium-independent vasodilation (drug-induced
increase in Qaw, ΔQaw). With this approach the investigators will test the hypothesis that in
stable ICS-naïve COPD patients, endothelium-dependent vasodilation is restored with a
glucocorticoid/long-acting beta-agonist preparation, presumably resulting from the
glucocorticoid component.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami
Treatments:
Adrenergic Agents Adrenergic Agonists Adrenergic beta-Agonists Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Glucocorticoids Salmeterol Xinafoate